Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo
in reducing cocaine use as measured by cocaine urine results and self-report days of use.
Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo
in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the
Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention
during the first four weeks of treatment will mediate galantamine's efficacy in reducing
cocaine use.